Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers
The transfer of atomoxetine into human milk is minimal, with a 0.19% RID, well below the 5% safety threshold for psychoactive medications. The minimal transfer suggests that maternal atomoxetine use poses a very low risk to breastfed infants, making it a suitable choice for medication management of ADHD in lactating women.
Authors
- Kaytlin Krutsch (ORCID: https://orcid.org/0000-0002-7453-2582)
- Palika Datta (ORCID: https://orcid.org/0000-0002-1009-1079)
- Amy L. Stark (ORCID: https://orcid.org/0000-0001-5257-6632)
- Emily M. Yamada
- Shraddha Trehan
Institutions
- Texas Tech University (US)
- University of Health Sciences and Pharmacy (US)
- Indiana University School of Medicine
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1097/jcp.0000000000002109
- Primary Topic
- Maternal Mental Health During Pregnancy and Postpartum
- Type
- article
- Field-Weighted Citation Impact
- 0.00